Veramorph is a specialty pharmaceutical start-up that has developed a universal oral drug delivery platform. They are focused on expanding opportunities for commercializing oral drug products through their internal pipeline of orally reformulated products and partnerships with pre-clinical compounds. Veramorph aims to address pain points in the universal oral drug delivery industry, such as poorly soluble drugs and the limited compatibility of current excipients.

Their DPOD platform, or Dissociating Polymeric Oral Dosage, is a game-changer in oral drug delivery. It overcomes the limitations of current technologies by using environmentally responsive cross-linked polymers. These polymers are synthesized without the drug and contain nanopores that transform the drug into nanocrystals.

Upon oral dosing, the cross-links rapidly dissociate and release the drug and polymers, ensuring sustained high levels of supersaturation. Veramorph's DPODs have the unique ability to achieve a combination of high drug loading, fast dissolution rate, and prolonged supersaturation, effectively transforming poorly soluble drug substances into highly effective oral drug products. With their diversified and differentiated product portfolio, Veramorph is making significant contributions to the field of oral drug delivery.

Headquartered in Mansfield, Massachusetts, Veramorph is at the forefront of revolutionizing oral drug delivery with their universal oral drug delivery platform